AnaSpec Introduces Labeled RGD Peptide for In Vivo Imaging

Released on: October 16, 2007, 10:26 am

Press Release Author: AnaSpec Inc.

Industry: Biotech

Press Release Summary: Leveraging its dual expertise in peptides and detection
reagents, AnaSpec has released c[RGDyK(HiLyte FluorTM 750)], a labeled RGD peptide
that has produced significant imaging results in a recent in vivo research study.

Press Release Body: October 15, 2007 - San Jose, CA

Leveraging its dual expertise in peptides and detection reagents, AnaSpec has
released c[RGDyK(HiLyte FluorTM 750)], a labeled RGD peptide that has produced
significant imaging results in a recent in vivo research study.

Extracellular matrix proteins containing the Arg-Gly-Asp (RGD) motif, and integrin
receptors which bind this sequence, constitute a major recognition system for cell
migration and adhesion processes. In fibronectins and other proteins, the RGD
binding sequence is found at the apex of a loop. Such conformation has been found
to allow for high affinity selectivity to integrin receptors. Cyclic peptides have
been shown to be more stable than linear peptides. In the case of RGD cyclic
peptide c(RGDyK), its structure also confers increased affinity and selectivity for
integrin αvβ3 both in cell culture and in living subjects. The conjugate,
c[RGDyK(HiLyte FluorTM 750)], binds specifically to some tissues in organs that are
known to be rich in integrin αvβ3 (see Figure 1).

In vivo testing of this HiLyte FluorTM 750-labeled was performed by the University
of South Florida. The results were presented in a late-breaking poster at the 20th
American Peptide Symposium.

Company Info
AnaSpec, Inc. is a leading provider of integrated proteomics solutions to
pharmaceutical, biotech, and academic research institutions throughout the world.
With a vision for innovation through synergy, AnaSpec focuses on three core
technologies: peptides, detection reagents (dyes, assay kits, & antibodies), and
combinatorial chemistry.

For more information, visit www.anaspec.com

Reference:
Chen, X., P. Conti, and R. Moats, Cancer Res. 64, 8009 (2004).


Web Site: http://www.anaspec.com

Contact Details: Ping Yang
AnaSpec Marketing
2149 O\'Toole Ave.
San Jose, CA 95131
1-408-452-5055(Tel)
1-408-452-5059(Fax)

  • Printer Friendly Format
  • Back to previous page...
  • Back to home page...
  • Submit your press releases...
  •